Business context and reporting period
The supplied filing is Sigma Labs, Inc.’s Form 10-Q for the quarter ended March 31, 2012—not a filing for Nexttrip, Inc. Investors should verify the company and filing identity.
Sigma Labs develops manufacturing and materials technologies, including In Process Quality Assurance (IPQA), and also earns revenue from consulting. Sumner and La Mancha, acquired on December 31, 2011, provide public- and private-sector consulting services. The 2012 quarter includes these subsidiaries; the 2011 reported comparison does not.
Financial performance and liquidity
| Metric | Q1 2012 | Q1 2011 |
|---|---|---|
| Revenue | $86,092 | $57,039 |
| Cost of service revenue | $85,816 | $17,181 |
| Gross profit (margin) | $276 (0.3%) | $39,858 (69.9%) |
| General and administrative expense | $131,434 | $118,074 |
| Payroll expense | $123,490 | $139,752 |
| Net loss | $(254,737) | $(239,968) |
| Net cash used in operations | $(136,765) | $(46,688) |
Revenue rose about 51%, while net loss increased about 6%. The sharp rise in service costs reduced gross margin to nearly break-even. The reported 2011 comparison excludes Sumner and La Mancha; pro forma 2011 results assuming their inclusion from January 1 were revenue of $291,661 and net loss of $235,092.
At March 31, 2012, cash was $516,690, current assets $627,723, current liabilities $83,972, and working capital $543,751. Cash declined $136,423 during the quarter from $653,113 at year-end. Total liabilities were $83,972, consisting of accounts payable and accrued expenses; the filing reports no credit facility and no investing cash flows. No interest-bearing debt is shown.
Outlook, risks and unusual items
- Management expected general and administrative, payroll, and non-cash compensation expenses to increase during 2012 as the acquired businesses and operations expand.
- Management anticipated up to $141,848 in 2012 revenue from one active B6 Sigma consulting contract and up to $582,000 from three Sumner contracts as of May 3, 2012. La Mancha had no active contracts. These are expectations, not guaranteed revenue.
- The company had not begun selling its technologies. Management aimed to commercialize IPQA and other technologies during 2012, but stated that profitability and additional capital were uncertain.
- The filing identifies going-concern uncertainty: the company had sustained losses since inception and depended on expanding income opportunities. Management believed available funds and expected consulting receipts would cover operating expenses for the balance of 2012, but said future liquidity depended on consulting revenue and securities sales. No third-party funding commitments or credit facilities were disclosed.
- Fixed-price consulting work carries cost-estimation and delivery risk; underestimated costs could reduce or eliminate contract profits. Other disclosed risks include uncertainty in commercialization and the possibility that actual results differ materially from forward-looking statements.
- After quarter-end, 7,000,000 unvested shares valued at $140,000 were cancelled or forfeited. Management reported disclosure controls effective at a reasonable assurance level and no material quarterly change in internal control over financial reporting.
Important facts for investors to verify
- Confirm that this Sigma Labs filing, rather than a Nexttrip filing, is the intended document.
- Assess the comparability of year-over-year results given the December 2011 acquisitions; review the pro forma figures and the acquired companies’ subsequent contribution.
- Verify the status, remaining value, costs, and collectability of the cited consulting contracts and whether new contracts or financing were obtained.
- Evaluate cash runway, continuing operating cash burn, and the going-concern and capital-raising risks.
- Track progress toward technology commercialization and whether service costs can be managed to generate sustainable gross profit.